Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AKCEA-TTR-LRx reduces TTR levels in Phase 1
October 2019
SHARING OPTIONS:

BOSTON & CARLSBAD, Calif.—Ionis Pharmaceuticals Inc. and Akcea Therapeutics Inc., an affiliate of Ionis, shared data regarding the Phase 1 trial of AKCEA-TTR-LRx at the Heart Failure Society of America 23rd Annual Scientific Meeting in Philadelphia last month. The compound, under co-development by the two companies for the treatment of TTR amyloidosis or ATTR, is an antisense drug developed with Ionis’ LICA technology platform. The results showed that patients receiving 45mg monthly injections saw a mean reduction in TTR levels of 86 percent at week 13, while patients receiving 90mg monthly saw a mean reduction of 94 percent at week 13. Patients who received a single 120mg injection saw a mean TTR reduction of 86 percent at week four. Ionis and Akcea intend to begin the Phase 3 program for AKCEA-TTR-LRx later this year.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.